RACGP logo

This activity is an online medical education activity that aims to provide education to general practitioners (GPs) on the use of sodium glucose co-transporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus (T2DM), with a particular emphasis on the use of these agents in patients with diabetic kidney disease and heart failure.

Learning outcomes

By the end of this activity, participants will be able to:

  • Compare and contrast current clinical trial data for antidiabetic medications with respect to their impact on kidney disease and heart failure
  • Select the appropriate class(es) of antidiabetic medication(s) for patients with kidney disease and heart failure and explain the rationale for medication choice
  • Review local and international treatment guidelines for T2DM and discuss the potential for inequities of access to appropriate healthcare in New Zealand
  • Identify when specialist referral is warranted for diabetes-associated comorbidities/complications
RACGP logo

This education is a Category 3 Educational Activity in the RNZCGP CPD Programme. It will take approximately 1 hour to complete.

Other healthcare professionals can still enrol and complete this course. You will receive a certificate upon completion.


If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.